All In Biotech

Drug Trial Radar · NCT01082302

Pharmacokinetic Study of Topically Applied Veregen 15% Compared With Oral Intake of Green Tea Beverage

An Open-Label, Single-Center Phase I (Phase IV/ USA) Study to Assess the Pharmacokinetic Profile of Topically Applied Veregen® 15% in Patients With External Genital and Perianal Warts Compared With Oral Intake of a Green Tea Beverage

Last checked: Nov 19, 2026Latest source record: Sep 8, 2010 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

43

Actual

Start

Jan 2010

Primary completion

Aug 2010

Study completion Aug 2010

Sponsor

Lead sponsor
MediGeneIndustry
Sponsor type
Industry
Collaborators
Charité Research Organisation GmbH
First posted
Mar 8, 2010

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 4
Allocation
Non randomized
Model
Single group
Masking
None
Primary purpose
Treatment
Who can join
All sexes, from 18 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

This open, monocentric study is designed to investigate plasma concentrations of certain catechins after topical application of Veregen 15% ointment to genital or perianal warts in comparison to catechin plasma concentrations after oral intake of a defined dose of green tea beverage. The study is intended to demonstrate that topical administration of Veregen 15% induces catechin plasma concentrations lower or equivalent to those that can be reached with normal consumption of green tea.

Conditions

  • Genital Warts
  • Perianal Warts

Interventions

  • Polyphenon E (Veregen) 15% ointmentDrug

    3 times daily application on genital and perianal warts over 7 days

  • Green Tea Beverage with defined catechin contentOther

    3 times daily oral intake over 7 days

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Pharmacokinetic profile of green tea catechinsTime frame: Day 1/2 and Day 7/8

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Charité Research Organisation

    Berlin, Germany

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.